GenOway's first half 2025 results: revenue down 10%

GenOway, a specialist in predictive preclinical solutions, announced revenue of €9.6 million for the first half of 2025, a 10% decrease from €10.7 million the previous year. Despite this decline, the company's performance is at the upper end of its forecast range.

The sales reorganization and new marketing plan, implemented as part of the ROUTE 50+ strategic plan, had a temporary impact on the company's performance. However, they should lay the foundations for a return to growth. The second half of the year looks promising, with contracts expected to increase by more than 10% and savings of €0.9 million in 2025.

GenOway confirms its solid profitability and invests in a new building to double its production capacity. The company aims to achieve a turnover of at least €50 million by 2028.